Trials / Unknown
UnknownNCT02940132
A Study of SC10914 in Patients With Advanced Solid Tumors
Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics/ Pharmacodynamics and Preliminary Efficacy of SC10914 in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
SC10914 is a potent selective PARP-1 and PARP-2 inhibitor. This study aims to determine the safety , tolerability , pharmacokinetic/pharmacodynamics profile of increasing doses of SC10914 when administered orally to patients with advanced solid tumors. Furthermore, the safety and efficacy of SC10914 in patients with advanced solid tumors and negative expression of ATM or BRCA1 or BRCA2 mutation will be evaluated in expanded cohorts to establish the Recommended Phase 2 Dose(RP2D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SC10914 | SC10914 will be administered orally. |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2018-03-01
- Completion
- 2018-05-01
- First posted
- 2016-10-20
- Last updated
- 2017-12-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02940132. Inclusion in this directory is not an endorsement.